Legacy ramps up preparations for new Russian track and trace sterilisation regulations
Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.
Legacy Pharmaceuticals, a global contract manufacturer of sterile/aseptic pharmaceutical products in ampoules and vials, has announced that preparations to meet the new Russian track and trace regulation, Federal Law No. 425-FZ, are well advanced.
Due to be introduced in January 2020, the regulation sets a new bar for serialization, compliance reporting and data management.
“The Russian regulations are even more stringent that the newly implemented serialization systems Legacy recently installed to meet the EU Falsified Medicines Directive in 2018. The addition of cryptographic coding in particular, which adds another layer to security, is a significant technical challenge,” says Legacy CEO Mike Danzi.
“However, Russia has always been one of our key markets and we are committed to ensure our longstanding customers can continue to rely on our products. We are preparing to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding. New Bosch serialization and aggregation equipment has already been installed and certified on three packaging lines. Complex labelling containing a wide range of readable/variable data and DMC-codes is now possible.
Two types of tamper-evident labels are available for different packaging materials including cartons, styrofoam boxes, and bottles. Legacy is committed to the Russia market, and to leading the way to comply with the new serialization requirements.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.